Compare CPSS & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPSS | IPSC |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.1M | 189.7M |
| IPO Year | 2010 | 2021 |
| Metric | CPSS | IPSC |
|---|---|---|
| Price | $8.20 | $2.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 8.3K | ★ 929.1K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.07 |
| EPS | ★ 0.59 | 0.11 |
| Revenue | ★ $393,506,000.00 | $6,589,000.00 |
| Revenue This Year | $139.27 | $1,589.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $13.31 | $25.23 |
| Revenue Growth | 11.79 | ★ 194.81 |
| 52 Week Low | $6.67 | $0.34 |
| 52 Week High | $10.51 | $2.97 |
| Indicator | CPSS | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 37.83 | 65.03 |
| Support Level | $7.38 | $0.49 |
| Resistance Level | $8.60 | $2.71 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 3.60 | 71.50 |
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.